| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AKRO | Common Stock | Award | $21.2K | +1.06K | +0.42% | $19.94 | 252K | Jun 28, 2024 | Direct | F1, F2 |
| transaction | AKRO | Common Stock | Sale | -$117K | -5K | -1.99% | $23.40 | 247K | Jul 1, 2024 | Direct | F4, F5 |
| holding | AKRO | Common Stock | 20K | Jun 28, 2024 | By EA Irrevocable Trust | F3 | |||||
| holding | AKRO | Common Stock | 20K | Jun 28, 2024 | By CM Irrevocable Trust | F3 | |||||
| holding | AKRO | Common Stock | 20K | Jun 28, 2024 | By JL Irrevocable Trust | F3 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Dr. Young is voluntarily reporting the acquisition of these shares on June 28, 2024 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d). |
| F2 | In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on June 28, 2024. |
| F3 | These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| F4 | The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 27, 2023, previously adopted by the Reporting Person. |
| F5 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.185 to $23.680, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 5. |